By Drug Target Review2025-05-08T08:30:19
A new study reveals how tumours hijack fat metabolism to suppress immune responses - and how a novel antibody, PLT012, may reverse this effect, offering new hope for treating immunotherapy-resistant cancers.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2023-07-04T09:00:08
Sponsored by SB Drug Discovery
2024-02-08T11:07:39
Sponsored by Samplix ApS
2023-09-27T13:56:39
Sponsored by Euretos
2023-03-02T13:57:58
Sponsored by Cell Signaling Technology
2025-07-30T08:00:00
Sponsored by Wuxi Biologics
2025-04-02T14:00:00
Sponsored by Eurofins Discovery
Site powered by Webvision Cloud